中药产业是否已显疲态,曾经在国内叱咤风云的中成药,在国际市场上已是英雄迟暮,美人白发。站在激烈竞争的国际市场上,中国、日韩、欧美三分天下的局面已经形成,但我们清楚地看到我们的势力是如何的弱小,每年200多亿美元的市场,我们仅得5%左右。我们一直在努力,但我们的中药国际化进程同样遭遇尴尬。有人说,入世后对我国医药的冲击是较小的,但这不能成为我们中药只占全球市场砩的借口,不能成为我们放松全球市场开拓的理由。如同其他的国粹一样,我们同样给予中药产业寄予太多的希望。如何把产业、资源优势变成 Whether the Chinese medicine industry has been significantly weakened, once in the country all-powerful proprietary Chinese medicines, in the international market is already heroic, white hair. China, Japan, South Korea, Europe and the United States have already formed a one-third position in the fiercely competitive international market. However, we have clearly seen how weak our forces are. With a market of more than 20 billion U.S. dollars each year, we only have 5% about. We have been working hard, but we are equally embarrassed in the process of internationalization of Chinese medicines. Some people say that the impact on China’s medicine after the accession to the WTO is small, but this can not be used as an excuse for our traditional Chinese medicine to account only for the global market. It can not be a reason for us to relax the global market. Like other national essences, we also give too much hope to the Chinese medicine industry. How to turn industry, resource advantages into